# Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment

> **NCT01134380** · — · COMPLETED · sponsor: **Biotronik France** · enrollment: 1500 (estimated)

## Conditions studied

- Coronary Artery Disease
- Acute Coronary Syndrome
- Genetic Resistance to Clopidogrel
- Compliance to Thienopyridine Treatment

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01134380
- **Lead sponsor:** Biotronik France
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2014-10-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01134380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01134380, "Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01134380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*